Deep Apple Therapeutics uses an integrated discovery engine combining ensemble cryo-EM, deep learning, and molecular docking screens of ultra-large libraries to discover novel small-molecule therapeutics. The platform moves from target identification to lead optimization in less than 12 months and is broadly applicable across disease areas. It is particularly suited to expedited hit-finding against integral membrane proteins and is advancing multiple programs focused on GPCR modulators with applications in metabolic disorders, inflammation, immunology, and endocrine diseases. The company is led by founding CEO Spiros Liras, Ph.D., and builds on academic co-founders Georgios Skiniotis (Stanford), Brian Shoichet (UCSF), and John Irwin (UCSF). Deep Apple intends to use the new funds to expand operations and accelerate its development efforts; the article reports a $52M Series A financing led by Apple Tree Partners.

Total raised

$52M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2023